To test the hypothesis of improved anti-tumour immunity with triplet therapy, preclinical studies have examined co-administration of BRAF/MEKi and anti-PD-1 or anti-PD-L1 antibodies in melanoma mouse models. This evidence concerns the gene CD274 and melanoma.